Edwards Lifesciences Corporation (EW) Covered Calls

Edwards Lifesciences Corporation is the global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. It is a pioneer in the development of heart valve therapies, particularly transcatheter aortic valve replacement (TAVR). The company’s portfolio includes surgical heart valves, transcatheter mitral and tricuspid therapies, and advanced hemodynamic monitoring systems used to measure a patient’s cardiovascular function during surgery.

You can sell covered calls on Edwards Lifesciences Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for EW (prices last updated Tue 1:10 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Core Business and Products

Edwards Lifesciences Corporation (EW) is a dominant force in the medical technology sector, specifically within the structural heart market. The company is best known for its SAPIEN family of valves, which led the revolution in transcatheter aortic valve replacement (TAVR). This technology allows physicians to replace a failing heart valve via a catheter, avoiding the need for invasive open-heart surgery. Edwards operates through four main pillars: TAVR, Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. Its TMTT segment is a high-growth area focused on treating mitral and tricuspid valve diseases, which represent a significant unmet medical need globally.

The company also maintains a strong presence in the surgical heart valve market, providing tissue-based replacement valves for patients who require traditional surgical intervention. Additionally, its Critical Care unit provides sophisticated hemodynamic monitoring platforms, such as the HemoSphere system. These tools utilize AI-driven algorithms to provide clinicians with real-time insights into a patient’s fluid status and cardiac output, helping to prevent complications during high-risk surgeries. Following the 2024 divestiture of a portion of its critical care business to Becton Dickinson, Edwards has increasingly concentrated its resources on its high-margin, high-growth structural heart therapies.

Competitive Landscape

Edwards Lifesciences operates in a high-barrier-to-entry market defined by intensive R&D and strict regulatory oversight. Its primary rival in the TAVR space is Medtronic, whose Evolut platform is the main alternative to Edwards' SAPIEN valves. In the broader structural heart and mitral repair market, the company competes fiercely with Abbott Laboratories, which holds a leading position in mitral clip technology. Other significant competitors in the medical device and surgical instrument space include Boston Scientific and Stryker Corporation.

Edwards differentiates itself through its "singular focus" strategy. Unlike its more diversified peers like Intuitive Surgical, which focuses on robotic assistance across various specialties, Edwards dedicates nearly all its resources to cardiovascular innovation. This specialization has fostered deep relationships with interventional cardiologists and surgeons, creating a powerful "clinician preference" moat. Furthermore, the company’s massive clinical data library—built over decades of PARTNER trials—provides a level of evidence-based credibility that newer entrants struggle to match, allowing Edwards to maintain premium pricing and market leadership in the premium valve segment.

Strategic Outlook and Innovation

The strategic roadmap for Edwards Lifesciences is centered on the expansion of TAVR into "asymptomatic" and "low-risk" patient populations, significantly increasing its total addressable market. The company is also making a massive push into the tricuspid space with its EVOQUE valve, the first transcatheter therapy authorized for tricuspid replacement. By 2026, Edwards is increasingly leveraging digital health and AI to move from being a device manufacturer to a "solutions provider," integrating machine learning into its monitoring systems to predict hypotension and other adverse cardiac events before they occur.

Innovation efforts are also focused on "next-generation" materials, such as the RESILIA tissue technology, which is designed to improve the durability of bioprosthetic valves and reduce the need for re-intervention. The company is also exploring minimally invasive ways to treat heart failure through its acquisitions in the structural heart space. By maintaining a heavy reinvestment rate—often spending 17-18% of revenue on R&D—Edwards ensures a steady pipeline of breakthrough therapies. This commitment to innovation positions the company to lead the shift toward personalized, catheter-based cardiac care, ensuring long-term growth in an aging global population.

Want more examples? EVX Covered Calls | EWA Covered Calls